Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Long-Term Deferred Tax (2023)

Day One Biopharmaceuticals (DAWN) has disclosed Long-Term Deferred Tax for 1 consecutive years, with $94.5 million as the latest value for Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax changed N/A year-over-year to $94.5 million; the TTM value through Dec 2023 reached $94.5 million, changed N/A, while the annual FY2023 figure was $94.5 million, N/A changed from the prior year.
  • Long-Term Deferred Tax was $94.5 million for Q4 2023 at Day One Biopharmaceuticals.
  • The five-year high for Long-Term Deferred Tax was $94.5 million in Q4 2023, with the low at $94.5 million in Q4 2023.